Dr. Christopher P. Recknor, M.D.
Internal Medicine (Internal Medicine Physician)
Medicare and federal program status
Opted out of Medicare from October 1, 2013 through October 1, 2027. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly.
Source: CMS Medicare Opt Out Affidavits (record last updated November 14, 2025). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
GA license 040982
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $1,785,864 in research payments for these studies, mostly to the institutions running them.
- A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06299098 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are…
Amgen Inc. - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimer…
E.r. Squibb & Sons, L.l.c. - A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06976216
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.